SecBot SecBot
8-K ·Filed Mar 31, 2026

KOD

Kodiak Sciences Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001193125-26-134854
earnings-rerun-backfill
Actionable Insight ▲ Bullish

The significant clinical success in the GLOW2 study and the accelerated BLA timeline are major value drivers that overshadow the modest EPS miss. The strengthened cash position supports the company's ambitious development plans. Traders should focus on upcoming catalysts: topline data from the DAYBREAK study (wet AMD) expected in Q3 2026 and from the PEAK study (MESI) in Q4 2026.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$42.81
T+0 close · Mar 31, 2026 · via day close
Latest settled
−11.84%
T+60 · $37.74
Vs SPY
−25.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $42.81entry
  2. T+1 · 8mo ago −5.09%α −5.17% · $40.63
  3. T+5 · 7mo ago −1.05%α −4.82% · $42.36
  4. T+20 · 7mo ago +2.01%α −7.71% · $43.67
  5. T+60 · 5mo ago −11.84%α −25.22% · $37.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kodiak Sciences reported Q4 2025 net loss of $56.7M ($1.04/share), missing consensus by $0.03, driven by increased R&D spend. The filing was dominated by positive clinical news: strong Phase 3 GLOW2 topline results for Zenkuda (tarcocimab) in diabetic retinopathy, showing 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001), with an 85% risk reduction in sight-threatening complications. The company announced an accelerated path toward a multi-indication BLA submission and ended the year with $209.9M in cash after a $173M equity raise.

Key Financial Metrics

EPS
−$1.04
est −$1.01 · -3.0%
Revenue
$0.00
est $0.00 · 0.0%
Rating
strong beat

Key Facts

  • Positive Phase 3 GLOW2 topline results for Zenkuda in diabetic retinopathy: 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001).
  • 85% risk reduction in sight-threatening complications with Zenkuda vs. sham (2.4% vs. 15.8%, p=0.0001).
  • Company announced an accelerated timeline for a multi-indication Biologics License Application (BLA) submission for Zenkuda.
  • Completed a $173M follow-on equity offering in December 2025, ending the year with $209.9M in cash, up from $72.0M in Q3.
  • Q4 2025 net loss was $56.7M ($1.04/share), missing consensus of $-1.01/share, due to higher R&D expenses of $45.5M (up from $31.8M YoY).

Financial Impact

Net loss of $56.7M ($1.04/share) for Q4 2025, missing consensus by $0.03. R&D expenses increased 43% YoY to $45.5M. Cash position improved to $209.9M after a $173M equity raise.

epsr_and_d_expensescash_position

Risk Factors

  • The stock has a high short interest, and future dilution is possible as the company will likely need to raise more capital to fund late-stage trials and a potential commercial launch.
  • The upcoming DAYBREAK study in wet AMD is a critical hurdle; failure to meet its primary endpoint could significantly impact the stock despite the GLOW2 success.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-134854
Document: kod-20260331.htm0001193125-26-134854
Document: 0001193125-26-134854-index-headers.html0001193125-26-134854
Document: 0001193125-26-134854-index.html0001193125-26-134854
Document: 0001193125-26-134854.txt0001193125-26-134854
8-K Data (Synthetic)0001193125-26-134854

Track record

13 reports on KOD

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $111.19 −5.97% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $111.19 −1.54% settles Dec 15
  3. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $111.19 +0.00% settles Dec 14
  4. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $111.19 +3.82% settles Dec 8
  5. Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $111.19 −26.76% settles Nov 18
  6. Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
  7. Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
  8. Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $111.19 +23.65% ▼ −0.36% −0.32% vs SPY
  9. Aug 13, 202613w ago 8-K Neutral 4/10 No price data
  10. Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $111.19 +168.90% ▼ −19.85% −17.86% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026